Jardiance vs Mounjaro 2026: SGLT2 vs Dual GIP/GLP-1 Comparison Guide
Jardiance (empagliflozin), an SGLT2 inhibitor, and Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, represent two fundamentally different approaches to treating type 2 diabetes. According to the EMPA-REG OUTCOME trial published in the New England Journal of Medicine, Jardiance achieved a 38% reduction in cardiovascular mortality in patients with established heart disease. Meanwhile, the SURPASS-2 trial […]
Rybelsus vs Jardiance: Complete Type 2 Diabetes Comparison Guide
Rybelsus and Jardiance represent two leading oral medication options for managing blood glucose levels in adults with type 2 diabetes. Both drugs are FDA-approved to improve glycemic control when combined with diet and exercise, yet they work through fundamentally different mechanisms and offer distinct clinical advantages. According to the PIONEER 2 clinical trial, Rybelsus 14mg […]
